Radiopharmaceutical Licensing & Deal Landscape 2026

The Thesis: Oncology’s Hottest Modality

For most of the last decade, radiopharmaceuticals were a backwater — a complex, logistics-heavy corner of nuclear medicine that most large-cap pharma left to specialists. That ended abruptly. Since the end of 2023, every major oncology player has paid a premium to buy into the space, and the modality has become the most actively traded in cancer dealmaking. By our count, more than $13B has been committed across acquisitions and licensing deals in roughly two years, much of it for assets that were still in clinical development.

The catalyst was commercial proof. Novartis turned two acquired assets — Lutathera and Pluvicto — into genuine products, and Pluvicto in particular silenced the skeptics by reaching about $2.0B in 2025 sales, up 42% year over year. Once a radioligand therapy crossed the blockbuster threshold, the rest of the industry concluded the model worked and rushed to acquire a platform. For a cross-border advisory, the interesting questions are no longer whether the modality is real — it plainly is — but where the next licensable assets originate, what gates their value, and how a dealmaker captures the opening. That is this report.

What Radiopharmaceuticals Actually Are

A therapeutic radiopharmaceutical — in modern oncology, usually called a radioligand therapy — has two parts bolted together. A targeting molecule (a peptide, a small molecule, or an antibody) finds a marker that is over-expressed on the surface of a cancer cell. Chemically linked to it is a radioactive isotope that, once the molecule docks onto the tumour, delivers a cytotoxic dose of radiation precisely where it is needed. The appeal is selectivity: instead of flooding the whole body like chemotherapy, the drug behaves like a guided munition.

The single most important technical distinction in the field is the type of isotope, because it drives both the science and the dealmaking:

• Beta-emitters (e.g. lutetium-177, Lu-177). The established workhorse. Beta particles travel a relatively long range and deposit energy over many cell diameters — forgiving of imperfect targeting, well-understood, and the basis of both approved products (Pluvicto and Lutathera). Supply, while constrained, is comparatively more developed.
• Alpha-emitters (e.g. actinium-225, Ac-225). The next frontier. Alpha particles carry far more energy over a much shorter range — a few cell diameters — so they can be more lethal to the targeted cell and, in principle, harder for the cancer to repair or resist. The trade-offs are tighter therapeutic windows and, critically, a much scarcer isotope supply.

Read the deal wave through this lens and it makes sense. The acquirers were not just buying molecules; they were buying positions along the beta-to-alpha transition, and — increasingly — buying their way toward the isotopes that make alpha therapy possible at all.

The Approved Products & Pipeline

Two products carry the modality commercially, both Novartis-owned and both Lu-177 based:

• Lutathera (Lu-177 dotatate). Targets the somatostatin receptor and treats gastroenteropancreatic neuroendocrine tumours. It was the first-of-its-kind FDA-approved radioligand therapy and proved the commercial model, with Novartis guiding toward $1B-plus peak sales.
• Pluvicto (Lu-177 vipivotide tetraxetan). Targets prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer. After a slow, supply-limited launch, it found its stride: a March 2025 label expansion into an earlier-line setting broadened the patient pool, and full-year 2025 sales reached about $2.0B, up 42% in constant currency. It also became the first PSMA radioligand therapy approved in China, via the NMPA, in late 2025.

Behind them sits a deep pipeline. The most-watched late-stage assets came in through the deal wave — RayzeBio’s RYZ101 (an Ac-225 program in neuroendocrine tumours, now BMS-owned), POINT Biopharma’s PNT2002 (a Lu-177 PSMA asset, now Lilly-owned), and Fusion’s prostate-targeted radioconjugates (now AstraZeneca-owned). The pipeline’s center of gravity is prostate and neuroendocrine cancer today, but the targeting toolkit — PSMA, somatostatin receptors, fibroblast activation protein (FAP), and others — is being pointed at a widening set of solid tumours.

The M&A Wave That Defined the Modality

The modality’s arrival is best told through the transactions. Within about two years, four of the largest oncology companies each bought a radiopharma platform, usually at a steep premium to the target’s market price:

• Eli Lilly — POINT Biopharma (~$1.4B, Oct 2023). Lilly’s entry into the field, at $12.50 per share — an 87% premium — for POINT’s Lu-177 PSMA asset PNT2002 and its manufacturing base.
• Bristol Myers Squibb — RayzeBio (~$4.1B, Dec 2023). The landmark deal. BMS paid $62.50 per share — roughly double the pre-announcement price and more than triple the IPO price from just three months earlier — for RayzeBio’s actinium-225 platform and its lead asset RYZ101. It was the clearest signal that big pharma wanted alpha-emitter exposure.
• AstraZeneca — Fusion Pharmaceuticals (up to ~$2.4B, 2024). About $2B upfront — a roughly 97% premium — plus contingent value, for Fusion’s next-generation radioconjugates targeting prostate cancer. Completed June 2024.
• Novartis — Mariana Oncology (up to ~$1.75B, 2024). The incumbent reinforcing its lead: $1B upfront plus up to $750M in milestones for a preclinical radioligand pipeline, including a small cell lung cancer program.

Acquisitions were only half the story. The licensing and partnership flow was equally telling, because it shows large pharma renting optionality rather than buying it outright — exactly the structures a cross-border advisor works in. Novartis partnered with PeptiDream in a deal worth up to roughly $2.7B to co-develop macrocyclic-peptide radiopharmaceuticals, and Lilly struck collaborations with Aktis Oncology and Radionetics worth up to about $1.1B each. Sanofi moved through a licensing deal with RadioMedix and Orano Med on a lead-212 (alpha) asset for neuroendocrine tumours. The throughline: every modality leader concluded it needed both molecules and isotope access, and bought or licensed accordingly.

We track the broader transaction flow across modalities in our biotech licensing deal tracker, and the parallel dynamics in adjacent targeted modalities in our ADC market and licensing analysis and CAR-T market and licensing analysis.

The Deals at a Glance

The pattern is consistent: high premiums, a mix of beta- and alpha-emitter exposure, and a deliberate reach toward platforms and manufacturing rather than single molecules. Note the final row — the first signal that China is moving from buyer to seller in this space.

The Isotope Supply Crunch

If there is one issue that separates radiopharma diligence from any other modality, it is this: the drug cannot exist without a reliable supply of its isotope, and that supply is genuinely scarce. Radioisotopes decay continuously, so they cannot be stockpiled in the way a small molecule can — they must be produced, attached to the targeting molecule, shipped, and administered within a tight window dictated by the isotope’s half-life. The entire value chain is a logistics problem with a stopwatch attached.

The constraint bites hardest for actinium-225, the leading alpha-emitter. Global Ac-225 supply has historically depended on a handful of legacy sources, and demand from the expanding pipeline is outrunning new capacity. This is not a theoretical worry: RayzeBio — even under BMS ownership — had to pause enrolment in a Phase III trial of its lead asset because it could not secure enough actinium-225. When a modality leader with a major-pharma balance sheet is gated by isotope supply, every smaller player in the field is exposed to the same risk.

Even the more established lutetium-177 chain is strained. Producing it requires isotopically enriched targets, high-flux neutron sources, weeks-long irradiation cycles, and a thin specialised workforce. Layer in geopolitics — export controls on certain rare-earth feedstocks, and the fragility of any supply chain that depends on a small number of reactors — and isotope access becomes a strategic variable, not a procurement footnote. This is precisely why the deal wave was accompanied by a parallel manufacturing build-out: BMS opened an Indianapolis Ac-225 facility, Novartis broke ground on new radioligand sites in Indianapolis and Carlsbad, and Orano Med is constructing lead-212 capacity in France.

The commercial consequence is that radiopharma rewards vertical integration in a way most modalities do not. A company that controls its isotope source, its radiolabelling and finishing, and a distribution network capable of getting a short-lived dose to the patient on time owns something competitors cannot quickly replicate. That is part of why the acquirers paid up: they were not only buying a pipeline but buying a head start on a supply chain that takes years and heavy capital to stand up. For a licensor or licensee, the practical implication is that the deal terms must allocate isotope supply explicitly — who guarantees it, at what volumes, and what happens to milestones and royalties if a supply interruption stalls a trial or a launch. Those clauses are where radiopharma licences succeed or fail.

The Key Players

The competitive map now has a clear structure — a dominant incumbent, a cohort of large-cap challengers, and a layer of specialists and isotope suppliers underneath:

• Novartis — the incumbent. Built the modality commercially through its earlier acquisitions of Advanced Accelerator Applications (Lutathera) and Endocyte (Pluvicto), and keeps reinforcing its lead with the Mariana acquisition and the PeptiDream partnership. It is the company every challenger is measured against.
• The large-cap challengers — BMS, AstraZeneca, Lilly. Each bought its way in (RayzeBio, Fusion, POINT) and is racing to turn a clinical platform into approved products while securing isotope and manufacturing capacity.
• Isotope and manufacturing specialists. The often- overlooked but strategically central layer — the producers of Ac-225, Lu-177, and Pb-212 (e.g. Orano Med on the lead-212 chain), whose capacity decisions gate the whole field.
• The remaining independents. A thinning pool of clinical-stage radiopharma biotechs and platform companies — the next acquisition and licensing targets, which is exactly where sourcing work concentrates.

The China Cross-Border Angle

For a cross-border advisory, the most interesting development is that China is moving from spectator to participant on both sides of the radiopharma trade. As a market, the signal is Pluvicto’s late-2025 NMPA approval — the first PSMA radioligand therapy licensed in China — and Novartis’ decision to build a radiopharmaceutical production base there. As a source of assets, a domestic ecosystem is taking shape:

• Dongcheng Pharma (through its Lanacheng subsidiary) is developing a Lu-177 PSMA therapy positioned as a domestic competitor to Pluvicto.
• Grand Pharma has assembled a radiopharma footprint, including in-licensing a Lu-177 neuroendocrine-tumour asset from Germany’s ITM and acquiring an established Y-90 microsphere product.
• Full-Life Technologies — building both Lu-177 and Ac-225 programs — provided the breakthrough cross-border data point by out-licensing an asset to SK Biopharmaceuticals in a deal worth up to about $572M, including upfront and milestone payments.

The Full-Life transaction matters out of proportion to its size: it demonstrates that a Chinese radiopharma asset can clear the bar for an international licensing partner, which is the precondition for a real cross-border deal channel. The same playbook that now defines Chinese out-licensing in oncology more broadly — source an asset that has reached human proof-of-concept in China, then license ex-China or global rights — is beginning to apply to radiopharmaceuticals. We map that wider dynamic in our China out-licensing report.

The BD & Licensing Read

Stripped to its essentials, here is how a dealmaker should approach the radiopharmaceutical market in 2026:

• Underwrite the isotope, not just the molecule. The single most distinctive diligence task in this modality is securing and stress-testing the isotope supply. An asset’s value is capped by its weakest supply contract.
• Decide your alpha-vs-beta posture deliberately. Lu-177 assets are more de-risked on supply and clinical precedent; Ac-225 and other alpha assets carry higher upside and higher supply risk. The premium an acquirer pays should reflect which side of that line the asset sits on.
• Value manufacturing and territory, not just rights. Because radiopharma is a logistics business, control of manufacturing nodes and clear territorial splits (who can dose patients where, within the half-life window) are core value drivers, not afterthoughts.
• Watch China on both sides. As a commercialisation territory and as an early-asset source, China is now part of the radiopharma calculus — and the early movers (Full-Life to SK) are proving the channel works.

The structures that fit this modality best are the ones a specialist advisor lives in: option-to-license deals that let a partner watch an isotope supply mature before committing, territory-split licences that respect manufacturing geography, and partnerships that bundle a molecule with guaranteed isotope access. This is the core of what Vision Lifesciences does — see our in-licensing, out-licensing, and strategic partnerships services.

The Bottom Line

Radiopharmaceuticals have completed the journey from niche to must-have. The commercial proof — Pluvicto at about $2.0B and growing — and more than $13B in acquisitions and partnerships have made the modality a permanent fixture of oncology dealmaking rather than a passing fashion. The question for a dealmaker is no longer whether to be in the space, but how to enter it without inheriting the field’s defining risk.

It is worth being clear-eyed about the limits, too. Radiopharma is not a magic modality: it carries the same Phase III clinical risk as any drug, the launch ramps can be slow when supply and dosing infrastructure lag the label — Pluvicto’s own early launch was supply-limited before it accelerated — and the addressable patient populations for the lead indications, while valuable, are not unlimited. The premiums paid in the deal wave assume both that the isotope supply scales and that the targeting toolkit extends to new tumour types. Neither is guaranteed. The discipline, as with any hot modality, is to separate the assets where those assumptions are already being validated from the ones where the price simply extrapolates the hype.

That risk is the isotope supply chain — and it is also the source of durable advantage for those who navigate it well. The winners in the next phase will be the parties that pair the right molecule with secured isotope access, structure for manufacturing and territory, and source the next generation of assets early — increasingly including from China. If you are evaluating a radiopharmaceutical asset, platform, or cross-border licence, talk to our team.